Skip to main content

Recombinant Vaccine Confers More Protection Against Influenza

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 14, 2023.

By Elana Gotkine HealthDay Reporter

THURSDAY, Dec. 14, 2023 -- A high-dose recombinant influenza vaccine is more effective than standard-dose vaccine among adults aged 50 to 64 years, according to a study published in the Dec. 14 issue of the New England Journal of Medicine.

Amber Hsiao, Ph.D., M.P.H., from the Kaiser Permanente Vaccine Study Center in Oakland, California, and colleagues conducted a cluster-randomized observational study to compare the effectiveness of recombinant vaccines as compared with standard-dose vaccines against influenza-related outcomes in adults under the age of 65 years. During the 2018 to 2019 and 2019 to 2020 influenza seasons, facilities routinely administered either a high-dose recombinant influenza vaccine (Flublok Quadrivalent) or one of two standard-dose influenza vaccines to adults aged 50 to 64 years and 18 to 49 years.

Data were included for 1,630,328 individuals aged 18 to 64 years who received vaccines (632,962 in the recombinant-vaccine group and 997,366 in the standard-dose group). The researchers identified 1,386 and 2,435 cases of polymerase chain reaction (PCR)-confirmed influenza diagnosed in the recombinant-vaccine and standard-dose groups, respectively. Among participants aged 50 to 64 years, 2.00 and 2.34 cases per 1,000 tested positive for influenza in the recombinant-vaccine and standard-dose groups, respectively (relative vaccine effectiveness, 15.3 percent). The relative vaccine effectiveness against influenza A was 15.7 percent in the same age group. Compared with the standard-dose vaccines, the recombinant vaccine was not significantly more protective against influenza-related hospitalization.

"Participants between the ages of 50 and 64 years who received the recombinant vaccine had more protection against confirmed influenza than those who received a standard-dose vaccine," the authors write.

The study was funded by Sanofi, the manufacturer of the Flublok vaccine.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted December 2023

Read this next

SARS-CoV-2 Vaccine Does Not Increase New-Onset Seizure Risk

TUESDAY, April 30, 2024 -- There is no risk for new-onset seizure incidence for individuals receiving a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine versus...

Most Moms-to-Be Interested in RSV Vaccination During Pregnancy

THURSDAY, April 25, 2024 -- More than half of women who are pregnant or planning to become pregnant are very likely to get vaccinated against respiratory syncytial virus (RSV)...

2011 to 2021 Saw Increase in Vaccination Timeliness for Infants

MONDAY, April 15, 2024 -- From 2011 to 2021, there was an increase in vaccination timeliness among U.S. children aged 0 to 19 months, according to a study published online April...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.